Invention Grant
- Patent Title: Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents
-
Application No.: US14715115Application Date: 2015-05-18
-
Publication No.: US09694091B2Publication Date: 2017-07-04
- Inventor: Martin G. Pomper , Sangeeta Ray , Ronnie C. Mease , Catherine Anne Foss
- Applicant: THE JOHNS HOPKINS UNIVERSITY
- Applicant Address: US MD Baltimore
- Assignee: THE JOHNS HOPKINS UNIVERSITY
- Current Assignee: THE JOHNS HOPKINS UNIVERSITY
- Current Assignee Address: US MD Baltimore
- Agency: Michael Best & Friedrich LLP
- Agent Jeffrey W. Childers
- Main IPC: A61K51/04
- IPC: A61K51/04 ; A61K31/195 ; C07D257/00 ; A61K31/145 ; A61K31/395 ; A61K31/4402 ; A61K38/06 ; C07D213/38 ; C07D215/12 ; G01N33/574 ; C07D257/02 ; C07F13/00 ; C12Q1/37 ; G01N33/60
Abstract:
The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
Public/Granted literature
Information query
